PharmaTelevision - Blair Jackson of Alkermes discusses their merger with Elan Drug Technologies to create Alkermes plc

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Blair Jackson of Alkermes discusses their merger with Elan Drug Technologies to create Alkermes plc

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Blair Jackson, Vice President of Business Development at Alkermes

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Alkermes products

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Oxford, England. On this show I have Blair Jackson, who is Vice President of Business Development and Program Leadership at Alkermes, welcome to the show.

Blair Jackson:

Thanks for having me.

Fintan Walton:

Blair, could you tell us a little bit more about Alkermes the company itself?

Blair Jackson:

Sure, Alkermes has been around for about 20-years or so and we were originally founded as a drug delivery company, and our original business model was to work with pharmaceutical companies and apply technology to their drugs to bring those to market and really to enhance patient outcomes. We worked in a variety of different technologies long-acting injectable, pulmonary delivery, transport across the blood-brain barrier, but we decided really about a decade ago to change our business strategy we recognized that if we wanted to drive our market cap and to really grow the company we needed to focus on proprietary product development. So we introduced and started working on our first product which was Vivitrol for the treatment of alcohol dependence and that took us about 8-years or so to bring that to marketplace but that was really a transformational event for the company and that allowed us to really test the waters with our own proprietary development. So over the last 20-years we've been quite successful in bringing a number of highly differentiated products to market, one being Risperdal-Consta with J&J which is marketed worldwide right now and sells about $1.5 billion, separately we work with Bydureon on Bydureon with Eli Lilly and Amylin Pharmaceuticals for the treatment of diabetes which was just recommended for approval in Europe and we hope to have approval shortly in the United States. So those are two really exciting drug delivery products that are coming to market and will drive near-term growth for Alkermes, and then Vivitrol as I mentioned earlier is a product that we have approved in United States in 2006 for alcohol dependence and we've been commercializing ourselves for a couple years as well.

Fintan Walton:

Okay, so you have a mixture of having your own products as well as developing products in partnership with other pharmaceutical companies?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Blair C Jackson

Vice President

Blair C. Jackson leads the business development and program leadership efforts at Alkermes. This encompasses all licensing efforts, new product evaluation, alliance management, and proprietary product development. Since joining Alkermes in 1999, he has served in various roles within the company in both a scientific and corporate capacity. Blair received a B.A. in Biochemistry from the University of Calgary, a B.A. in Chemical Engineering and an M.B.A. from the University of Alberta, and a Masters in Chemical Engineering Practice from the Massachusetts Institute of Technology.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Alkermes

Alkermes Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes Vivitrol for alcohol dependence and manufactures Risperdal-Consta for schizophrenia and bipolar I disorder. Alkermes's robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.